Thanks to the advance of psychedelic medicine, "brain injury awareness" is about more than highlighting a problem. It's also about new hope for sufferers.
Exploring the companies and themes that make up this emerging and exciting new sector
Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates
Enveric Bioscience announces the publishing of four PCT applications by the World Intellectual Property Organization.
Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013
Wesana Health reports positive feedback from FDA on pre-IND meeting regarding development of SANA -013 and is anticipating commencing a clinical trial in Q4 2022.
How Capital Markets Are Fueling Psychedelic Medicine Growth
The psychedelic medicine industry is growing. There was a wave of new psychedelic firms going public, with big names like MindMed and Atai Life Sciences listing on major stock exchanges like the NASDAQ, and increased acceptance of psychedelics by institutional investors.
Incannex observes substantial reduction in AHI in preliminary results of clinical trial assessing IHL-42X in patients with OSA; proceeds to pivotal studies
Incannex reports a strong clinical response in its trial of a cannabinoid combination product IHL-42X for sleep apnea.
Albert Labs (CSE:ABRT) Closes $4.7m Private Placement; Begins Trading on the Canadian Securities Exchange
UK-based Albert Labs announces its official trading date on Canada's CSE exchange. The Company will commence trading Thursday, March 11th under the symbol "ABRT"
Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets
Small Pharma announces two more planned clinical trials for 2022 from its pipeline of DMT-based drug candidates.
The Biden Strategy On Mental Health: Lots Of Bandaids, No Substance
With a mental health catastrophe in the United States spiraling out of control, the Biden "plan" is just more of what has failed.
Novamind to Conduct Phase II Psilocybin Trial for Major Depressive Disorder
Novamind announces it will conduct a Phase II clinical trial for the sponsor, Usona Institute, on a psilocybin-based therapy for MDD.
Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics
Incannex Healthcare to incorporate virtual reality in a new R&D partnership aimed at psychedelics-based therapies.
Apex Labs granted phase 2a Clinical Trial Application approval by Health Canada for treatment of PTSD in Veterans
Apex has secured its Veteran patient base, clinical trial location and Qualified Investigator for its phase 2a program expected to launch as early as Q2/Q3 2022.
Seelos Therapeutics Announces Year-End 2021 Business and Clinical Update
Seelos Therapeutics reports progress on several of its drug R&D initiatives, including preparing for a Phase IIb/Phase III trial of SLS-005 for ALS.